Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Summary

This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus may kill tumor cells expressing a gene called neurofibromin 1 (NF1) without affecting surrounding normal cells and may also help the body build an effective immune response to kill tumor cells.

Conditions

• Metastatic Malignant Peripheral Nerve Sheath Tumor
• Neurofibromatosis Type 1
• Recurrent Malignant Peripheral Nerve Sheath Tumor

Interventions

PROCEDURE

Computed Tomography

Undergo CT scan

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Given intratumorally

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT imaging

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Ultrasound Imaging

Undergo ultrasound imaging

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Biopsy

Undergo tissue biopsy

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Dusica Babovic-Vuksanovic, MD · Mayo Clinic

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-03-22

Primary Completion

2024-04-17

Completion

2024-04-17

FDA Drug

Yes

Countries

• United States

Study Locations